{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:47:04Z","timestamp":1793915224720,"version":"4.8.0"},"reference-count":36,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Allergy"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>About one\u2010tenth of patients with difficult\u2010to\u2010treat chronic rhinosinusitis with nasal polyps (CRSwNP) have comorbid non\u2010steroidal anti\u2010inflammatory drug\u2010exacerbated respiratory disease (NSAID\u2010ERD). Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)\u20104\/IL\u201013 receptor component, is an approved add\u2010on treatment in severe CRSwNP. This post hoc analysis evaluated dupilumab efficacy and safety in patients with CRSwNP with\/without NSAID\u2010ERD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were pooled from the phase 3 SINUS\u201024 and SINUS\u201052\u00a0studies in adults with uncontrolled severe CRSwNP who received dupilumab 300\u00a0mg or placebo every 2\u00a0weeks. CRSwNP, nasal airflow, lung function, and asthma control outcomes at Week 24 were evaluated, and treatment\u2013subgroup interactions were assessed for patients with and without NSAID\u2010ERD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 724 patients, 204 (28.2%) had a diagnosis of NSAID\u2010ERD. At Week 24, least squares mean treatment differences demonstrated significant improvements in nasal polyp score, nasal congestion (NC), Lund\u2013Mackay computed tomography, 22\u2010item Sinonasal Outcome Test (SNOT\u201022), Total Symptom Score (TSS), rhinosinusitis severity visual analog scale, peak nasal inspiratory flow (PNIF), six\u2010item Asthma Control Questionnaire score, and improvement in smell with dupilumab versus placebo (all\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&lt;\u00a0.0001) in patients with NSAID\u2010ERD. Treatment comparisons demonstrated significantly greater improvements with dupilumab in patients with versus without NSAID\u2010ERD for NC (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0= .0044), SNOT\u201022 (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.0313), TSS (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.0425), and PNIF (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a0.0123).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with uncontrolled severe CRSwNP, dupilumab significantly improved objective measures and patient\u2010reported symptoms to a greater extent in the presence of comorbid NSAID\u2010ERD than without. Dupilumab was well tolerated in patients with\/without NSAID\u2010ERD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/all.15067","type":"journal-article","created":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T04:26:45Z","timestamp":1630297605000},"page":"1231-1244","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":107,"title":["Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID\u2010ERD: Results from two randomized placebo\u2010controlled phase 3 trials"],"prefix":"10.1111","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3463-5007","authenticated-orcid":false,"given":"Joaquim","family":"Mullol","sequence":"first","affiliation":[{"name":"Rhinology Unit &amp; Smell Clinic, ENT Department Hospital Cl\u00ednic IDIBAPS Universitat de Barcelona CIBERES Barcelona Catalonia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6709-9795","authenticated-orcid":false,"given":"Tanya M.","family":"Laidlaw","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology Brigham and Women's Hospital, and Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4742-1665","authenticated-orcid":false,"given":"Claus","family":"Bachert","sequence":"additional","affiliation":[{"name":"Upper Airways Research Laboratory and Department of Otorhinolaryngology Ghent University Ghent Belgium"},{"name":"Division of ENT Diseases, CLINTEX Karolinska Institutet Stockholm Sweden"},{"name":"First Affiliated Hosptial Sun Yat\u2010sen University Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leda P.","family":"Mannent","sequence":"additional","affiliation":[{"name":"Global Clinical Development Sanofi, Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-2557","authenticated-orcid":false,"given":"G. Walter","family":"Canonica","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences Humanitas University, Personalized Medicine Asthma &amp; Allergy Unit\u2010IRCCS Humanitas Research Hospital, Rozzano Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph\u00a0K.","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology &amp; Head and Neck Surgery Eastern Virginia Medical School Norfolk Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9750-2346","authenticated-orcid":false,"given":"Jorge F.","family":"Maspero","sequence":"additional","affiliation":[{"name":"Allergy and Respiratory Medicine Fundaci\u00f3n CIDEA Buenos Aires Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7400-4993","authenticated-orcid":false,"given":"Cesar","family":"Picado","sequence":"additional","affiliation":[{"name":"Clinical &amp; Experimental Respiratory Immunoallergy IDIBAPS, Universitat de Barcelona, CIBERES Barcelona Catalonia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4136-4068","authenticated-orcid":false,"given":"Nadia","family":"Daizadeh","sequence":"additional","affiliation":[{"name":"Biostatistics Sanofi Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Ortiz","sequence":"additional","affiliation":[{"name":"Immunology and Allergy Medical Affairs Regeneron Pharmaceuticals, Inc. New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Li","sequence":"additional","affiliation":[{"name":"Global Medical Affairs Respiratory Sanofi Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Ruddy","sequence":"additional","affiliation":[{"name":"Clinical Sciences Global Development Regeneron Pharmaceuticals, Inc. Tarrytown New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Laws","sequence":"additional","affiliation":[{"name":"Immunology and Inflammation Sanofi Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1865-9861","authenticated-orcid":false,"given":"Nikhil","family":"Amin","sequence":"additional","affiliation":[{"name":"Clinical Sciences Global Development Regeneron Pharmaceuticals, Inc. Tarrytown New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00218-1"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.401"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.04.012"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.4193\/RHINOL\/18.067"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.013"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-030-21217-9_43"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201412-2278OC"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13685"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2018.06.006"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.08.020"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.2500\/ajra.2018.32.4498"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iac.2016.06.008"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.13599"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcibr1514013"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040925"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2016.12.027"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wjorl.2020.07.010"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2007.03.020"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.26377"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.10.043"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1323896111"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1324022111"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1298443"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"issue":"2","key":"e_1_2_11_26_1","article-title":"Biologics for chronic rhinosinusitis","volume":"29","author":"Chong LY","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_11_27_1","unstructured":"DUPIXENT\u00ae (dupilumab). Prescribing information Regeneron Pharmaceuticals. Revised June 2020. Accessed November 24 2020.https:\/\/www.regeneron.com\/sites\/default\/files\/Dupixent_FPI.pdf"},{"key":"e_1_2_11_28_1","unstructured":"DUPIXENT\u00ae (dupilumab). Summary of product characteristics Regeneron Pharmaceuticals. Revised June 2020. Accessed November 24 2020.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/dupixent\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S243053"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29137"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.12.014"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1945892420961969"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.09.042"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804093"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804092"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14050"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18031"}],"container-title":["Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15067","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/all.15067","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/all.15067","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T12:06:05Z","timestamp":1692965165000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/all.15067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/all.15067"],"URL":"https:\/\/doi.org\/10.1111\/all.15067","archive":["Portico"],"relation":{},"ISSN":["0105-4538","1398-9995"],"issn-type":[{"value":"0105-4538","type":"print"},{"value":"1398-9995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"2020-12-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}